Adage Reports 9.99% Stake in Immunic (IMUX) — 10.48M Shares
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 10,479,337 shares of Immunic, Inc. (IMUX), representing 9.99% of the outstanding common stock.
Rhea-AI Filing Summary
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 10,479,337 shares of Immunic, Inc. (IMUX), representing 9.99% of the outstanding common stock. The filing states this total includes 9,080,737 shares issuable upon exercise of warrants and that the percentage is calculated on an aggregate base of 95,817,536 shares outstanding as reported in the company prospectus.
The reporting persons disclose no sole voting or dispositive power and instead report shared voting and shared dispositive power for the reported shares. The filing also certifies the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.
Positive
- Beneficial ownership of 10,479,337 shares representing 9.99% of the class as reported.
- Includes 9,080,737 shares issuable upon exercise of warrants, disclosed transparently in the filing.
- Reporting architecture clearly identified (Adage Capital Management, L.P., Robert Atchinson, Phillip Gross).
Negative
- No sole voting or dispositive power reported; all authority is listed as shared.
- Position is 9.99%, which is just below the 10% mark used as a regulatory threshold in many contexts.
- Reported stake relies heavily on warrants, which affects actual current ownership and potential dilution dynamics.
Insights
TL;DR: Adage reports a sizeable 9.99% economic stake in Immunic, largely driven by warrant exercise, with only shared voting power.
The filing discloses a 10,479,337-share position representing 9.99% of the class based on an outstanding-share base of 95,817,536 and explicitly includes 9,080,737 shares issuable upon exercise of warrants held by Adage structures. Because the reported position is comprised primarily of warrant-derived shares and is reported as shared voting/dispositive power with 0 sole power, this is material from a disclosure perspective but does not signal unilateral control. Investors should note the stake size and warrant exposure when assessing potential dilution and influence.
TL;DR: The disclosure shows significant economic exposure but no sole control; governance influence appears shared.
The filing names Adage Capital Management, L.P., Robert Atchinson and Phillip Gross as reporting persons and documents that all voting and dispositive authority over the 10,479,337 shares is shared rather than sole. The inclusion of 9,080,737 warrant-issuable shares in the reported total is explicitly noted and the ownership percentage is calculated assuming exercise. From a governance standpoint, the position is meaningful but the absence of sole voting power indicates limited unilateral governance control based on the disclosed facts.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Adage Capital report in Immunic (IMUX)?
Who are the reporting persons named in the Schedule 13G/A for IMUX?
AI-generated analysis. How Rhea-AI works. Not financial advice.